Optimizerx Corp Stock Price, News & Analysis

OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, will participate in the RBC Capital Markets Global Healthcare Virtual Conference. CEO Will Febbo is scheduled for a fireside chat on May 19, 2021, at 8:00 a.m. ET. The presentation can be accessed live on the company's investor website. OptimizeRx offers a digital platform that connects healthcare providers and patients, enhancing medication affordability and adherence through innovative communication solutions. For updates, follow OptimizeRx on social media or visit their website.

OptimizeRx Corp. (Nasdaq: OPRX) reported a 48% revenue increase in Q1 2021, reaching $11.2 million compared to $7.6 million year-over-year. Gross profit rose 41% to $6.1 million, though GAAP net loss was $0.6 million or $(0.04) per share.

The company achieved cash flow positivity from operations at $1.7 million, bolstered by a successful equity offering raising $70.7 million. 33 enterprise contracts worth $25 million in annual value were secured. Cash and cash equivalents soared to $82.3 million by March 31, 2021.

OptimizeRx Corporation (Nasdaq: OPRX) will hold a conference call on May 6, 2021, at 4:30 p.m. Eastern to discuss its first quarter financial results for the period ending March 31, 2021. A press release with the financial results will precede the call, where management will address questions afterward. Interested parties can access the call via a toll-free number or the web. The company is recognized for its digital health solutions, connecting a significant network of healthcare providers and patients to enhance medication adherence.

OptimizeRx Corp. (Nasdaq: OPRX) has expanded its digital health platform through new health information technology partnerships, significantly increasing its reach to over 50% of oncologists in the U.S. This initiative is aimed at enhancing connections between life science companies and healthcare providers. The partnerships diversify the channel mix available for customer engagement, which is crucial for addressing the challenges of affordability and access in oncology. The new collaborations strengthen the company’s position in delivering personalized treatment resources at the point-of-care.

OptimizeRx Corp. (Nasdaq: OPRX) has secured 19 new enterprise-level deals in 2021, showcasing a strong conversion rate from its pipeline of 46 potential deals. The company aims to surpass last year's 86% renewal rate. The ongoing digital shift in healthcare, accelerated by COVID-19, has led to increased demand for its solutions, which enhance client engagement with healthcare providers. CEO William Febbo expressed optimism for continued growth, supported by consistent revenue streams from these enterprise deployments.

OptimizeRx Corp. (Nasdaq: OPRX) will present at the 33rd Annual ROTH Growth Conference virtually from March 15-17, 2021. The event will showcase various public and private companies, featuring a pre-recorded webcast from OptimizeRx available now on their website. CEO Will Febbo will engage in one-on-one meetings, highlighting the company's 2020 achievements, including a 76% revenue increase to $43.3 million and a robust sales pipeline exceeding $180 million. Attendees include institutional investors and analysts, emphasizing the event's significance.

OptimizeRx Corp. (Nasdaq: OPRX) reported a robust performance for Q4 2020 with revenues soaring 123% to $16.4 million, driving a full-year revenue increase of 76% to $43.3 million. The company's gross profit for Q4 rose 92% to $8.6 million, and GAAP net income was $1.4 million or $0.08 per diluted share. A significant cash infusion of $71 million from an equity offering supports future growth. With a pipeline exceeding $180 million and recognition from Deloitte as a top growth company, OptimizeRx plans for ongoing expansion and innovation in 2021.

OptimizeRx Corporation (Nasdaq: OPRX) announced that Angelo Campano, its senior vice president, has been named to MM+M’s 2021 ‘40 Under 40’ list for his notable contributions to healthcare marketing. This recognition highlights young leaders who have driven growth in the industry amid challenging conditions. Campano brings over 18 years of experience in digital channel partnerships, collaborating with 245 EHR platforms and 100 specialty pharma partners. His leadership has earned him accolades, including PM360’s ELITE Innovator Award in 2017.